Processa Pharmaceuticals (PCSA) Capital Leases (2024)

Processa Pharmaceuticals' (PCSA) quarterly Capital Leases came in at $487.0 in Q4 2024, down 77.54% on a QoQ basis from $2168.0 in Q3 2024.

Processa Pharmaceuticals (PCSA) Capital Leases (2024) Analysis & Trends

Processa Pharmaceuticals (PCSA) has 1 years of Capital Leases data on file, last reported at $487.0 in Q4 2024.

Quarterly Capital Leases changed N/A year-over-year to $487.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $487.0 (changed N/A YoY) and the FY2024 annual result came in at $487.0, changed N/A from the prior year.
Capital Leases declined to $487.0 in Q4 2024, from $2168.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $6107.0 in Q1 2024 to a low of $487.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-
10	Processa Pharmaceuticals	5.72 Mn	5.72 Mn	-

Download Data